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Breast cancer - overview
• Worldwide, the most 
common malignancy 
in women
• 20% of all cancers
• 36,000 cases 
diagnosed in England 
and Wales during 
year 2000
• 10% of the female 
population of Leeds 
Breast cancer overview
SURVIVAL
• Increasing age          











• Preferable measure for patient and clinician
• Separate studies are difficult to compare:
► Reliant on accurate recording of dates 
(birth, diagnosis, death)
► Different statistical methods










• Survival lowest in 
UK and Eastern 
Europe
• Variation by age 




• Focus on the comparison 
between deprivation 
groups
• Deprived in USA had 









• Survival in USA higher than all 17 European 
countries included 
• Pooled European five-year survival rate 10% 






• Survival lower than USA or Europe





• International collaboration of cancer registries
• In progress (results expected 2005)
• Comparable data
• Comparable statistical methods
• National and sub-national analyses
• Adequate adjustment for age at diagnosis
• Multi-variate analyses
• Inclusion of diagnostic delay and treatment
• Adjustment for deprivation
Implications from literature review
• Extend comparative studies to Australasia
• Important similarities 
► Nationalised health care
► Caucasian population
► National cancer registration
• Important differences
► Survival rates
► Deprivation gap in survival
Comparison of breast cancer 



















































































































Unequal    
five-year 
survival rates
• Describe epidemiology of breast cancer
• Quantify the Australian advantage
• Compare the proportion ‘cured’
• Investigate reasons for differences
► Between Australia and England
► Within Australia and England
• Investigate the role of within-country 
variability in international differences
Aims
• National data (‘big picture’) and registry 
data (detailed analyses)
• Incidence, relative survival and ‘cure’
• Several covariates:
► deprivation category
► age at diagnosis
► stage of disease at diagnosis
► screening history
► time period of diagnosis
Planned analysis
• Population 5.3 million (West Midlands)
6.4 million (New South Wales)
• Register c.3000 breast cancer cases per year
• Consistent geographic boundaries 1980-2004
• Screening history available for all women 
through national screening programme
West Midlands Cancer Intelligence Unit 
New South Wales Central Cancer Registry






Patient and tumour identifiers X X
Dates of birth, diagnosis and 
death or censoring
X X
Data quality indicators X X
Region/ State at diagnosis X
Area-based deprivation category X
Tumour characteristics X
Screening history X
• No individual measure in cancer registry data
• Area-based scores (census data)
• Several indices available 
► Carstairs, Townsend, IMD (England)
► Townsend, SEIFA (Australia)
• Several possible geographies
► English EDs (’91), OAs, Super-OAs (‘01), wards
► Australian Collection districts (CDs)
Measuring deprivation
• Relative survival analysis 
► Adjusts for background mortality
► Permits valid comparisons between different 
groups of cancer patients
► Country- and deprivation-specific life tables 
• Age standardisation of survival
• Cure analysis
► Testing of currently available models
► Development of a more robust cure model
Methods
Research conducted in collaboration with the
West Midlands Cancer Intelligence Unit
and the
New South Wales Central Cancer Registry 
Laura Woods is funded by a Medical Research 
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